Table 1.
Baseline characteristics in the clinical and metabolic profiles of the participants.
| Control group | T2DM group | |
|---|---|---|
| Physical and clinical aspects | ||
| Age (years) | 62.9 ± 1.8 | 70 ± 3∗ |
| Height (m) | 1.57 ± 0.01 | 1.6 ± 0.02 |
| Diagnosis of DMT2 (years) | — | 19.7 ± 5.5 |
| Smokers (n) | 2 | 0 |
| Pedometer (steps/day) | 4668 ± 973 | 7947 ± 2029 |
| IPAQ—inactive (%) | 13.3 | 0 |
| IPAQ—minimally active (%) | 33.4 | 25 |
| IPAQ—active (%) | 53.3 | 75 |
| Systolic BP (mmHg) | 117.1 ± 4.3 | 132 ± 3.6∗ |
| Diastolic BP (mmHg) | 73.9 ± 2.6 | 84.9±2.2∗∗ |
| Plasma lipoprotein levels | ||
| Cholesterol (mmol/L) | 192.1 ± 7.4 | 166.3 ± 13 |
| HDL (mmol/L) | 57.9 ± 3.2 | 55.7 ± 5.1 |
| LDL (mmol/L) | 116.2 ± 7.4 | 92.6 ± 9.2 |
| TG (mmol/L) | 106 ± 9.2 | 90 ± 6 |
Note. The values are presented as the mean ± SE. ∗p < 0.05 control vs. T2DM; ∗∗p < 0.01 control vs. T2DM. Data are represented as the mean ± SE of 10-12 participants per group. mmHg: millimeters of mercury.